The acquisition of the Big Blue® transgenic mutation models ensures the continued market provision of the Big Blue® transgenic assays for companies requiring mutagenicity assessment under the OECD 488 guideline. These studies play a central role in enabling risk assessments for materials where pre-existing data indicates a potential mutagenicity risk to human health and the environment. Transfer of the technology and establishment of laboratory proficiency was presented at SOT 2023 (link to poster) and expansion of concurrent study capacity is due Q1 2024.
The acquisition allows us to strengthen the Gentronix portfolio of OECD guideline genetic toxicology testing services while we are also increasing our capacity within existing service offerings. The addition of the Big Blue® transgenic mutation assays is another significant step forward for our business, enhancing our credentials as the leading specialist genetic toxicology contract research organisation.
We now have the capability to support clients from their very first genetic toxicology screens right through to helping manage complex mutagenicity risk assessments. If you would like more details on how Gentronix can support your project through the conduct of OECD 488 Big Blue® transgenic mutation assays, please contact a member of the team today.